article thumbnail

FDA Adds Delayed Gastric Emptying as Adverse Event on Semaglutide Label

Pharmacy Times

The label includes postmarking reports showing rare instances of pulmonary aspiration for patients undergoing procedures that require general anesthesia or deep sedation.

Labelling 139
article thumbnail

STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure

STAT

Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to expand the label for the blockbuster treatment. of those who received placebo. of those who received placebo.

Labelling 119
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Novo expands Wegovy’s US label to reduce cardiovascular events

Pharmaceutical Technology

Wegovy can now be used to reduce the risk of major cardiovascular events in obese or overweight patients with heart disease.

article thumbnail

Experts to come together for compliance event ‘validation ready’ global labeling systems  

pharmaphorum

Experts to come together for compliance event . exploring ‘validation ready’ global labeling systems . ? . A group of industry experts is set to explore how medical device, clinical trial and pharmaceutical companies can proactively manage labeling risk. Wokingham, United Kingdom —?27?April?2021?—

article thumbnail

Leqvio Gets Label Update For Earlier Use in Patients with Heart Disease

Drug Topics

Recent safety data also allowed four adverse events to be removed from the label.

article thumbnail

Novo Nordisk plans label expansion for Rybelsus following Phase III win

Pharmaceutical Technology

The oral semaglutide reduced the occurrence of major adverse cardiovascular events (MACE) by 14% in patients with type 2 diabetes.

article thumbnail

Neoadjuvant pembrolizumab improves event-free survival compared to adjuvant therapy in advanced resectable melanoma

Hospital Pharmacy Europe

For the current study, US researchers performed a randomised, phase 2, open-label trial, in patients with measurable stage IIIB to IVC melanoma that was amenable to surgical resection. The primary end point was set as event-free survival in the intention-to-treat population. After a median follow-up of 14.7 Citation Patel SP et al.